Tagged with

UAE Samer Al Hallaq, Gulf President of AstraZeneca, speaks about the company’s strategy to align its portfolio with the increasing presence of lifestyle diseases like diabetes, and how innovation is the driving force behind continued growth for the future.   Let’s begin by speaking a little bit about AstraZeneca’s global focus…

UAE Paolo Carli, Head of Middle East, KSA & Egypt for Merck Serono, speaks about the regions most pressing health issues—hypertension and diabetes— and how he thinks that collaboration of the industry with the government and educational institutes will help overcome this problem before it’s too late.   Our approach to…

Adimmune Corporation The president of Adimmune Corporation discusses how the avian flu outbreak of 2006/2007 changed the course of the drug manufacturing industry in Taiwan, what that meant for Adimmune, and how he plans to get Adimmune and the Taiwanese biotech industry on the map. Over the past few decades, how has…

Life Sciences The funding of Canada’s biotech industry has changed drastically in recent years. Peter Van Der Velden of Lumira Capital discusses those changes and how his venture capital business is adapting to this evolving environment. Lumira has been involved with numerous acquisitions over the years. Could you highlight a couple of…

CROs Riaz Bandali, President ESD of InVentiv Health Clinical discusses the ways in which the company’s unique combination of different technologies and capabilities will help lead the way to better healthcare and the ability to treat individuals more effectively. What was your initial mandate at InVentiv? Like many Canadian health and…

R&D Tony Cruz of Transition Therapeutics discusses the challenges of biotech companies in Canada and his company’s unique business model that has adapted to the changing needs of big pharma through risk mitigation. You founded Transition Therapeutics in 1998. What was the reasoning behind founding a biotech company focused on CNS…

medical tourism     The minister in charge of medical tourism in Taiwan speaks about the country’s advantages over its Asian neighbours, and how the new era of Taiwan’s medical services will make a difference for foreigners seeking medical treatment in the country.   Minister Wu, during our first interview with you…

This table shows the VAT rates applied to medicines in European countries as of 1 January 2013. (1) France: reimbursable medicines 2.1%; non-reimbursable medicines 7.0% (2) Ireland: oral medication 0%; other medication 23.0% (3) Lithuania: reimbursable medicines 5.0%; non-reimbursable medicines 21.0% Source: Tax data from each country

Biosimilars Dr. Liu, President and CEO of EirGenix, talks about why he sees Taiwan as the ideal market for a CDMO like Eirgenix, why he believes that despite the skepticism, biosimilars will be able to overcome the initial barriers, and where he sees EiGenix in the next several years. What has…

LifeLabs Sue Paish, Lifelabs’ Chief Executive Officer discusses the company’s recent purchase of BC Biomedical, why the market in BC and Ontario are so attractive, and the motivation behind LifeLabs’ collaboration with medical device companies. What have been some of LifeLabs’ key achievements over the last year? LifeLabs is the largest…

InterMune Michael Cloutier, President of InterMune, elaborates on the challenges of navigating the Canadian healthcare system as a small pharmaceutical company, and highlights some methods by which Canada can provide a stable environment for Canadian companies to grow. You have had an extensive and varied career, with positions in the Canadian…

R&D Whaijen Soo, Managing Director of Supra Integration and Incubation Center (Si2C) speaks about Taiwan’s biotech industry, emphasizing the need for risk tolerance and understanding investing rationale in propelling Taiwan’s industry to the global forefront.  Taiwan Supra Integration and Incubation Center (Si2C), was launched in November 2011 with the intention of…